Jim Simons’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-350,345
| Closed | -$771K | – | 4602 |
|
|
2022
Q2 | $771K | Buy |
350,345
+26,500
| +8% | +$52.9K | ﹤0.01% | 2878 |
|
|
2022
Q1 | $606K | Buy |
323,845
+500
| +0.2% | +$910 | ﹤0.01% | 3059 |
|
|
2021
Q4 | $708K | Buy |
323,345
+10,800
| +3% | +$29.2K | ﹤0.01% | 2901 |
|
|
2021
Q3 | $1.04M | Sell |
312,545
-79,084
| -20% | -$214K | ﹤0.01% | 2523 |
|
|
2021
Q2 | $1.05M | Sell |
391,629
-394,977
| -50% | -$892K | ﹤0.01% | 2642 |
|
|
2021
Q1 | $1.68M | Buy |
786,606
+280,217
| +55% | +$796K | ﹤0.01% | 2325 |
|
|
2020
Q4 | $1.25M | Buy |
506,389
+265,548
| +110% | +$522K | ﹤0.01% | 2390 |
|
|
2020
Q3 | $491K | Buy |
240,841
+143,395
| +147% | +$409K | ﹤0.01% | 2816 |
|
|
2020
Q2 | $288K | Buy |
97,446
+62,343
| +178% | +$170K | ﹤0.01% | 3057 |
|
|
2020
Q1 | $93K | Buy |
35,103
+9,803
| +39% | +$44.2K | ﹤0.01% | 3243 |
|
|
2019
Q4 | $126K | Buy |
25,300
+7,600
| +43% | +$41.1K | ﹤0.01% | 3275 |
|
|
2019
Q3 | $105K | Buy |
+17,700
| New | +$119K | ﹤0.01% | 3258 |
|
Jim Simons's ETTX Position: Q3 2022 in Review
Jim Simons sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q3 2022, closing a stake of 350,345 shares — an estimated $771K sold.
Jim Simons first reported a position in ETTX in Q3 2019 and held it in 12 quarters. The position peaked at $1.68M in Q1 2021. 0 funds tracked by Wall St. Rank hold ETTX as of Q3 2022.
- Jim Simons reported no remaining Entasis Therapeutics Holdings Inc. position as of Q3 2022 after selling out during the quarter.
- Jim Simons sold 350,345 Entasis Therapeutics Holdings Inc. shares in Q3 2022, an estimated $771K.
- Jim Simons first reported a position in Entasis Therapeutics Holdings Inc. in Q3 2019 and held it in 12 quarters.
- Jim Simons's Entasis Therapeutics Holdings Inc. position peaked at $1.68M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q3 2022.
Based on Renaissance Technologies's 13F filing for Q3 2022, filed 14 Nov 2022.